The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
US FDA approval based on NEURO-TTRansform Phase III results
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Subscribe To Our Newsletter & Stay Updated
